J7612 HCPCS Level II code: Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 0.5 mg
J7612 is the HCPCS code for “Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 0.5 mg” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J7612Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 0.5 mg
Short description: Levalbuterol non-comp con
HCPCS · United States
Medicare details
The indicators CMS publishes with J7612 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Special coverage instructions apply
- Medicare pricing
- Service not separately priced by Part B (e.g., services not covered, bundled, used by Part A only, etc.)
- Type of service
- Medical care; Lump sum purchase of DME, prosthetics, orthotics
- BETOS category
- Drugs Administered through DME
- Added
- Jan 1, 2005
Where J7612 sits
- 1J codesDrugs administered other than orally
- 2Active code J7612Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 0.5 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J7612 mean?
J7612 is the HCPCS code for “Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 0.5 mg” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J7612?
CMS lists J7612’s Medicare coverage as “Special coverage instructions apply” and its pricing as “Service not separately priced by Part B (e.g., services not covered, bundled, used by Part A only, etc.)”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J7612
All J codesJ7606Formoterol fumarate, inhalation solution, fda approved final product, non-compounded, administered through dme, unit dose form, 20 microgramsJ7607Levalbuterol, inhalation solution, compounded product, administered through dme, concentrated form, 0.5 mgJ7608Acetylcysteine, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per gramJ7609Albuterol, inhalation solution, compounded product, administered through dme, unit dose, 1 mgJ7610Albuterol, inhalation solution, compounded product, administered through dme, concentrated form, 1 mgJ7611Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mgJ7613Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mgJ7614Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 0.5 mgJ7615Levalbuterol, inhalation solution, compounded product, administered through dme, unit dose, 0.5 mgJ7620Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dmeJ7622Beclomethasone, inhalation solution, compounded product, administered through dme, unit dose form, per milligramJ7624Betamethasone, inhalation solution, compounded product, administered through dme, unit dose form, per milligram